Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT06815471

PHASE2

CRF2 Agonist for the Treatment of Worsening Heart Failure

Sponsor: Corteria Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)

Official title: Corticotrophin Releasing Factor 2 for the Treatment of Worsening Heart Failure (WHF) - The CRAFT-WHF Study

Key Details

Gender

All

Age Range

18 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

300

Start Date

2025-08-07

Completion Date

2026-12

Last Updated

2026-04-08

Healthy Volunteers

Conditions

Worsening Heart Failure

Interventions

DRUG

COR-1167

28-day treatment

DRUG

Placebo

28-day treatment

Inclusion Criteria: * Signed written informed consent * Heart failure hospitalization (HFH) during previous 12 months * Prescribed an oral loop diuretic for at least 1 month preceding the index event * NT-proBNP ≥1,000 pg/mL or BNP ≥250 pg/mL * Requires treatment with i.v. diuretics for volume overload * At least 1 risk factor for diuretic resistance * Admitted to the hospital not more than 48 hours prior to randomization Exclusion Criteria: * Index event primarily triggered by an acute event (e.g. AMI, PE, arrhythmia) * Requirement for i.v. inotropic therapy or i.v. vasodilators, mechanical ventilation, high-flow oxygen therapy, or NIV * Requirement for, or planned use of LVADs, IABP, or any type of MCS * History of solid organ transplant or active on a transplant list * SBP \<100 mmHg * eGFR \< 20 mL/min/1.73 m2 * CABG, PCI, implantation of CRT, heart valve procedure or any cardiac surgery within 1 month prior to screening or planned during the study * Severe stenotic cardiac valvular disease * Severe chronic pulmonary disease requiring chronic steroid therapy or chronic oxygen therapy (\> 2 L/min) * Uncorrected severe hyperthyroidism or hypothyroidism * Severe restrictive, obstructive, or infiltrative cardiomyopathy * Body weight \< 70 kg * Use of any investigational drug(s) within 5 half-lives of screening * At high risk of death (defined as life expectancy ≤1 year) from causes other than heart failure or any disease that, in the opinion of the Investigator, will preclude their safe participation in this study, and will make implementation of the protocol or interpretation of the study results difficult * Presence of any other conditions (e.g. geographic, social) actual or anticipated, that the Investigator feels would restrict or limit the subject's participation or compliance with all study procedures Subject is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study

Locations (55)

Indiana University Health Methodist Hospital

Indianapolis, Indiana, United States

Wayne State University - Detroit Receiving Hospital

Detroit, Michigan, United States

Wayne State University - Sinai Grace Hospital

Detroit, Michigan, United States

Cone Health Moses Cone Hospital

Greensboro, North Carolina, United States

NC Heart and Vascular Research, LLC

Raleigh, North Carolina, United States

Ohio State University

Columbus, Ohio, United States

South Oklahoma Heart Research, LLC

Oklahoma City, Oklahoma, United States

Fakultní nemocnice Brno

Brno, Czechia

Sdružené zdravotnické zařízení Krnov

Krnov, Czechia

Fakultní nemocnice Ostrava

Ostrava, Czechia

Nemocnice Slaný

Slaný, Czechia

Aleksandre Aladashvili Clinic LLC

Tbilisi, Georgia

LTD "Israeli-Georgian Medical Research Clinic Healthycore"

Tbilisi, Georgia

Acad. G. Chapidze Emergency Cardiology Center LTD, Department of Internal Medicine and Medical Research

Tbilisi, Georgia

Acad. G.Chapidze Emergency Cardiology Center, LTD, Department of Multi-center Clinical Trials

Tbilisi, Georgia

Bokhua Memorial Cardiovascular Center LTD

Tbilisi, Georgia

St. Michael's Hospital LLC

Tbilisi, Georgia

Tbilisi Heart and Vascular Clinic, LTD

Tbilisi, Georgia

Georgian Dutch Hospital

Tbilisi, Georgia

LTD Tbilisi Heart Center

Tbilisi, Georgia

Semmelweis Egyetem, Általános Orvostudományi Kar, Városmajori Szív- és Érgyógyászati Klinika

Budapest, Hungary

Budapesti Uzsoki Utcai Kórház, Kardiológia Osztály

Budapest, Hungary

Pécsi Tudományegyetem, Klinikai Központ, I. sz. Belgyógyászati Klinika

Pécs, Hungary

Szegedi Tudományegyetem, Általános Orvostudományi Kar, Családorvosi Intézet

Szeged, Hungary

Zala Vármegyei Szent Rafael Kórház, Kardiológiai Osztály

Zalaegerszeg, Hungary

Klinika Kardiologii i Chorób Wewnętrznych z Oddziałem Intensywnego Nadzoru Kardiologicznego (OINK), Uniwersytecki Szpital Kliniczny w Białymstoku

Bialystok, Poland

I Klinika Kardiologii, Uniwersyteckie Centrum Kliniczne

Gdansk, Poland

SP ZOZ Szpital Uniwersytecki w Krakowie

Krakow, Poland

Zespół Opieki Zdrowotnej w Klodzku, Oddzial Kardiologii

Kłodzko, Poland

II Klinika Kardiologii, SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi

Lodz, Poland

Kliniczny Szpital Wojewódzki nr 2 im. Św. Jadwigi Królowej w Rzeszowie

Rzeszów, Poland

Oddział Kliniczny Kardiologii i Intensywnej Terapii Kardiologicznej

Torun, Poland

Instytut Chorób Serca, Zakład Badań Klinicznych Chorób Układu Krążenia, Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu

Wroclaw, Poland

Emergency County Clinical Hospital Arad, Cardiology department

Arad, Romania

Institutul de Urgenta pentru Boli Cardiovasculare "Prof. Dr. C.C. Iliescu", Cardiologie 1

Bucharest, Romania

Institutul de Urgenta pentru Boli Cardiovasculare "Prof. Dr. C.C. Iliescu", Cardiologie 3

Bucharest, Romania

Spitalul Clinic Colentina

Bucharest, Romania

Craiova County Emergency Clinical Hospital

Craiova, Romania

Spitalul Clinic Municipal de Urgenta Timisoara

Timișoara, Romania

Clinical Hospital Center "Dr Dragisa Misovic Dedinje"

Belgrade, Serbia

Institute for Cardiovascular Diseases Dedinje

Belgrade, Serbia

University Clinical Center of Serbia, Clinic for Cardiology, Department for the testing and treatment of congenital and acquired heart defects

Belgrade, Serbia

University Clinical Center of Serbia, Clinic for Cardiology, Emergency Cardiology Department

Belgrade, Serbia

University Clinical Center of Serbia, Clinic for Cardiology, Heart Failure Ward

Belgrade, Serbia

University Clinical Center Kragujevac, Clinic for Cardiology

Kragujevac, Serbia

General Hospital Leskovac, Cardiology Department

Leskovac, Serbia

University Clinical Center Nis, Clinic for Cardiology

Niš, Serbia

Institute For Treatment and Rehabilitation "Niska Banja"

Niška Banja, Serbia

Hospital Universitario Ramon y Cajal

Fuencarral-El Pardo, Madrid, Spain

Hospital Universitario Puerta de Hierro Majadahonda

Majadahonda, Madrid, Spain

Hospital Clínico Universitario Virgen de la Arrixaca

El Palmar, Murcia, Spain

Hospital Clínico Universitario de Valencia

Valencia, Valencia, Spain

Hospital Universitario Hospital Virgen del Rocío

Seville, Spain

Consorcio Hospital General Universitario de Valencia

Valencia, Spain

Hospital Universitari i Politecnic La Fe

Valencia, Spain

Clinical Research Directory

CRF2 Agonist for the Treatment of Worsening Heart Failure

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (55)